Hypertrophic Cardiomyopathy: Causes, Investigations, and Treatment
Published: 2021-12-20
Page: 309- 320
Issue: 2021 - Volume 4 [Issue 2]
Omar Elsaka *
Department of Cardiology, Mansoura University, Faculty of Medicine, Mansoura Manchester Medical Program (MMMP), Mansoura, Egypt.
*Author to whom correspondence should be addressed.
Abstract
Background: Hypertrophic cardiomyopathy (HCM) is the most common hereditary heart disease with a variety of genotypes and phenotypes. In previous terms, hypertrophic obstructive cardiomyopathy and idiopathic hypertrophic subaortic stenosis are no longer used to describe this business. Patients may or may not have a ventricular outflow tract (LVOT). Restlessness or LVOT inhibition occurs in 70% of patients and is the most common cause of heart failure. The pathology of HCM includes left ventricular hypertrophy with or without right ventricular hypertrophy, contractile mitral valve advancement, flexible and flexible LVOT inhibition, mitral valve recurrence, diastolic dysfunction, myocardial ischemia, and Includes fibrosis. A complete understanding of pathology and pathophysiology is essential for neural control and surgery.
Conclusion: Hypertrophic Cardiomyopathy requires invasive treatment. Alcohol Septal ablation and surgery are two common methods of invasive treatment.
Keywords: Heart failure, hypertrophic cardiomyopathy, left ventricular outflow obstruction, mitral regurgitation, systolic anterior motion.